Annovis Bio Secures US Patent for Buntanetap Targeting Neurological Damage from Brain Infections

Annovis Bio has obtained a U.S. patent for its drug buntanetap, which is designed for the prevention and treatment of neurological injuries caused by brain infections. The announcement highlights the company’s efforts to expand the potential applications of its therapeutic candidate in addressing conditions linked to brain health.

The newly granted patent covers the use of buntanetap in treating neurological damage resulting from infections affecting the brain. This development adds to Annovis Bio’s intellectual property portfolio and underscores its focus on advancing treatments for neurodegenerative diseases and related conditions. Buntanetap, which has been under investigation for its ability to improve axonal transport and reduce inflammation, is being explored as a possible solution for mitigating neurological injuries associated with infectious diseases that impact brain function.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 2, 2026

Author

GOAI